Clinical Trials Logo

Mild Cognitive Impairment (MCI) clinical trials

View clinical trials related to Mild Cognitive Impairment (MCI).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05594355 Active, not recruiting - Clinical trials for Mild Cognitive Impairment (MCI)

Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI

Start date: April 16, 2021
Phase: Phase 4
Study type: Interventional

Mild Cognitive Impairment (MCI) is the moderate impairment of a mental abilities to perform intellectual activities eg memory, calculation, communication... MCI is a disorder that can occur earlier than dementia such as Alzheimer's disease. It is believed that there are several factors involved such as inflammation and oxidative stress which is the production of reactive oxygen species that damage cells. This clinical study tries to evaluate that a treatment already approved by the AEMPS, EGb 761® (Tebofortan), could reduce the levels of markers of inflammation and oxidation in the blood.